- Home
- SLDP vs FULC Comparison
SLDP vs FULC Comparison
Compare SLDP & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLDP | FULC |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 718.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SLDP | FULC |
|---|---|---|
| Price | $3.11 | $8.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 3.8M | 980.9K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.88 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $2.32 |
| 52 Week High | $8.86 | $15.74 |
Technical Indicators
Market Signals| Indicator | SLDP | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 35.70 |
| Support Level | $2.92 | $6.33 |
| Resistance Level | $4.70 | $8.50 |
| Average True Range (ATR) | 0.19 | 0.82 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 3.29 | 12.08 |
Price Performance
Historical ComparisonAbout SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.